Compară metode
Examinează metodele selectate una lângă alta; rândurile care diferă sunt evidențiate.
| Instrument de screening pentru simptome premenstruale× | Chestionar privind calitatea vieții specifică menopauzei× | |
|---|---|---|
| Domeniu | Obstetrică și ginecologie | Obstetrică și ginecologie |
| Familie | Process / pipeline | Process / pipeline |
| Anul apariției≠ | 2003 | 1996 |
| Autorul original≠ | Steiner, M., Macdougall, M., & Brown, E. | Hilditch, J. R., Lewis, J., Peter, A., van Maris, B., Ross, A., Franssen, E., Guyatt, G. H. |
| Tip | Self-report | Self-report |
| Sursa seminală≠ | Steiner, M., Macdougall, M., & Brown, E. (2003). The Premenstrual Symptoms Screening Tool (PSST) for clinicians. Archives of Women's Mental Health, 6(3), 203-209. DOI ↗ | Hilditch, J. R., Lewis, J., Peter, A., van Maris, B., Ross, A., Franssen, E., Guyatt, G. H., Lethargy, S., & Improvement, T. (1996). A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas, 24(3), 161-175. DOI ↗ |
| Denumiri alternative | PSST, Premenstrual Symptom Screening | MENQOL, Menopause Quality of Life |
| Înrudite | 3 | 3 |
| Rezumat≠ | The Premenstrual Symptoms Screening Tool (PSST) is a brief, 19-item self-report questionnaire designed to screen for premenstrual dysphoric disorder (PMDD) and assess the severity of premenstrual symptoms. Developed by Steiner, Macdougall, and Brown in 2003, the PSST efficiently identifies women with clinically significant cyclical mood and physical symptoms warranting diagnostic evaluation and potential pharmacological or psychological treatment. | The Menopause-Specific Quality of Life Questionnaire (MENQOL) is a 29-item self-report instrument designed to assess quality of life in women experiencing menopausal symptoms. Developed by Hilditch and colleagues in 1996, the MENQOL captures four interrelated symptom domains: vasomotor symptoms (hot flushes, night sweats), psychosocial symptoms (mood, stress, anxiety), physical symptoms (fatigue, aches, sleep), and sexual symptoms. It is the primary menopause-specific outcome measure used in hormone replacement therapy trials and menopause research. |
| ScholarGateSet de date ↗ |
|
|